Overview
- Amazon Pharmacy is now delivering Eli Lilly’s newly approved Foundayo pill the same day in many cities and dispensing it at One Medical clinic kiosks, with insured co-pays often near $25 and cash prices from $149 to $349 depending on dose.
- A Nature study of nearly 28,000 23andMe users tied a GLP1R gene variant to a small extra weight loss on GLP-1 drugs and linked a GIPR variant to higher odds of vomiting on tirzepatide, underscoring that genetic effects are real but modest.
- A six-month prospective cohort reported for the European Congress on Obesity found substantial fat loss with minimal lean muscle loss on semaglutide or tirzepatide when paired with resistance training and adequate protein intake.
- A small retrospective case series presented at the Obesity Medicine Association meeting found some patients kept losing weight and maintained blood pressure, A1c, and triglyceride gains after extending GLP-1 doses to every other week or longer.
- Competition and access are shifting fast as Novo Nordisk’s Wegovy pill, approved earlier, is sold through subscription partners and, in an indirect comparison, was reported by Novo to show about 3.2% more weight loss than Foundayo, while Foundayo can be taken any time of day and is spreading through Amazon, GoodRx, Ro, and Lilly’s own pharmacy.